menu
    • menu
    [{"orgOrder":0,"company":"Corvidia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"D6PV","moa":"Apolipoprotein C-III","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Corvidia Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Corvidia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Corvidia Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2020","type":"Not Applicable","leadProduct":"BI 1701963","moa":"SOS1","graph1":"Oncology","graph2":"Phase I","graph3":"Forma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Forma Therapeutics \/ FORMA Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Forma Therapeutics \/ FORMA Therapeutics"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Olutasidenib","moa":"IDH-1","graph1":"Oncology","graph2":"Phase II","graph3":"Forma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Forma Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Forma Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"FT-4202","moa":"Pyruvate kinase","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Forma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Forma Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Forma Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"NewCo","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Divestment","leadProduct":"FT-4202","moa":"RBC pyruvate kinase","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Forma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Forma Therapeutics \/ NewCo","highestDevelopmentStatusID":"9","companyTruncated":"Forma Therapeutics \/ NewCo"},{"orgOrder":0,"company":"Dicerna Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"DCR-A1AT","moa":"Alpha-1 antitrypsin protein","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I\/ Phase II","graph3":"Dicerna Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Dicerna Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Dicerna Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"FT-4202","moa":"PKR","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Forma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Forma Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Forma Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"FT-6876","moa":"CBP\/p300","graph1":"Oncology","graph2":"Preclinical","graph3":"Forma Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Forma Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Forma Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordisk \/ Not Applicable"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Olutasidenib","moa":"IDH-1","graph1":"Oncology","graph2":"Phase II","graph3":"Forma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Forma Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Forma Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Dicerna Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Nedosiran","moa":"LDH","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Dicerna Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Dicerna Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Dicerna Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Insulin icodec","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Not Applicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordisk \/ Not Applicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Corvidia Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Acquisition","leadProduct":"Ziltivekimab","moa":"IL-6","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Novo Nordisk","amount2":2.1000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":2.1000000000000001,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Novo Nordisk","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Novo Nordisk"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"FT-4202","moa":"PKR","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Forma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Forma Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Forma Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Insulin icodec","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Not Applicable"},{"orgOrder":0,"company":"Dicerna Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Nedosiran","moa":"LDH","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Dicerna Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Dicerna Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Dicerna Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Undisclosed","year":"2020","type":"Not Applicable","leadProduct":"Fleroxacin","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Novo Nordisk \/ Not Applicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordisk \/ Not Applicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Staten Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"SST-5058","moa":"apoC3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Novo Nordisk","highestDevelopmentStatusID":"6","companyTruncated":"Novo Nordisk \/ Novo Nordisk"},{"orgOrder":0,"company":"Dicerna Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"RG6346","moa":"HBsAg-mRNA","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Dicerna Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Dicerna Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Dicerna Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Concizumab","moa":"Tissue factor pathway","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Not Applicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordisk \/ Not Applicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Insulin icodec","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Not Applicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"Large molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Antibodies","moa":"","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Novo Nordisk","highestDevelopmentStatusID":"1","companyTruncated":"Novo Nordisk \/ Novo Nordisk"},{"orgOrder":0,"company":"Dicerna Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Nedosiran","moa":"LDH","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Dicerna Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Dicerna Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Dicerna Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Olutasidenib","moa":"IDH-1","graph1":"Oncology","graph2":"Phase II","graph3":"Forma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Forma Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Forma Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"DENMARK","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Semaglutide","moa":"GLP-1 receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Not Applicable"},{"orgOrder":0,"company":"Dicerna Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"RG6346","moa":"HBsAg-mRNA","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Dicerna Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Dicerna Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Dicerna Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"FT-4202","moa":"PKR","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Forma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Forma Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Forma Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"FT-4202","moa":"PKR","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Forma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"oral","sponsorNew":"Forma Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Forma Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Semaglutide","moa":"GLP-1 receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Novo Nordisk","highestDevelopmentStatusID":"8","companyTruncated":"Novo Nordisk \/ Novo Nordisk"},{"orgOrder":0,"company":"Dicerna Pharmaceuticals","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"RG6346","moa":"HBsAg-mRNA","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Dicerna Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Dicerna Pharmaceuticals \/ Roche","highestDevelopmentStatusID":"7","companyTruncated":"Dicerna Pharmaceuticals \/ Roche"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordisk \/ Not Applicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordisk \/ Not Applicable"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"FT-4202","moa":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Forma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Forma Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Forma Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"FT-4202","moa":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Forma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Forma Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Forma Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Acquisition","leadProduct":"Semaglutide","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Novo Nordisk","amount2":1.8,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":1.8,"dosageForm":"Tablet","sponsorNew":"Novo Nordisk \/ Novo Nordisk","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordisk \/ Novo Nordisk"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Public Offering","leadProduct":"FT-4202","moa":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Forma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Forma Therapeutics \/ Jefferies","highestDevelopmentStatusID":"9","companyTruncated":"Forma Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Acquisition","leadProduct":"Semaglutide","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Novo Nordisk","amount2":1.8,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":1.8,"dosageForm":"Tablet","sponsorNew":"Novo Nordisk \/ Novo Nordisk","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordisk \/ Novo Nordisk"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Semaglutide","moa":"GLP-1 receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Novo Nordisk \/ Not Applicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordisk \/ Not Applicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordisk \/ Not Applicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Somapacitan","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordisk \/ Not Applicable"},{"orgOrder":0,"company":"Dicerna Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Nedosiran","moa":"LDH","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Dicerna Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Dicerna Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Dicerna Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordisk \/ Not Applicable"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"FT-7051","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Forma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Forma Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Forma Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"DENMARK","productType":"Peptide","year":"2021","type":"Collaboration","leadProduct":"Semaglutide","moa":"GLP-1 receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Gilead","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Gilead"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordisk \/ Not Applicable"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"FT-4202","moa":"PKR","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Forma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Forma Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Forma Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Dicerna Pharmaceuticals","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Acquisition","leadProduct":"Lumasiran","moa":"HO-1","graph1":"Genetic Disease","graph2":"Approved","graph3":"Dicerna Pharmaceuticals","amount2":0.23999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0.23999999999999999,"dosageForm":"Subcutaneous Injection","sponsorNew":"Dicerna Pharmaceuticals \/ Royalty Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Dicerna Pharmaceuticals \/ Royalty Pharma"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordisk \/ Not Applicable"},{"orgOrder":0,"company":"Dicerna Pharmaceuticals","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"DCR-LIV2","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"Dicerna Pharmaceuticals","amount2":0.17000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","amount2New":0.17000000000000001,"dosageForm":"","sponsorNew":"Dicerna Pharmaceuticals \/ Boehringer Ingelheim","highestDevelopmentStatusID":"4","companyTruncated":"Dicerna Pharmaceuticals \/ Boehringer Ingelheim"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"DENMARK","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Ziltivekimab","moa":"Il-6","graph1":"Nephrology","graph2":"Phase II","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Novo Nordisk \/ Not Applicable"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Olutasidenib","moa":"IDH-1","graph1":"Oncology","graph2":"Phase II","graph3":"Forma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Forma Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Forma Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordisk \/ Not Applicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Heartseed","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"Allogeneic iPSC-derived Cardiomyocytes","moa":"Angiogenic factors secretion","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Novo Nordisk","amount2":0.59999999999999998,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.59999999999999998,"dosageForm":"Intramyocardial Injection","sponsorNew":"Novo Nordisk \/ Novo Nordisk","highestDevelopmentStatusID":"6","companyTruncated":"Novo Nordisk \/ Novo Nordisk"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Etavopivat","moa":"PKR","graph1":"Hematology","graph2":"Phase II\/ Phase III","graph3":"Forma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Forma Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Forma Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordisk \/ Not Applicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Lumen Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Novo Nordisk","highestDevelopmentStatusID":"4","companyTruncated":"Novo Nordisk \/ Novo Nordisk"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordisk \/ Not Applicable"},{"orgOrder":0,"company":"Dicerna Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Belcesiran","moa":"Alpha-1 antitrypsin protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Dicerna Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Dicerna Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Dicerna Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Prothena","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"IRELAND","productType":"Large molecule","year":"2021","type":"Acquisition","leadProduct":"PRX004","moa":"ATTR protein","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Novo Nordisk","amount2":1.2,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":1.2,"dosageForm":"Intravenous Infusion","sponsorNew":"Novo Nordisk \/ Novo Nordisk","highestDevelopmentStatusID":"6","companyTruncated":"Novo Nordisk \/ Novo Nordisk"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Hemab Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"DENMARK","productType":"Large molecule","year":"2021","type":"Series A Financing","leadProduct":"Monoclonal-bispecific Antibody-based Therapeutics","moa":"","graph1":"Hematology","graph2":"Undisclosed","graph3":"Novo Nordisk","amount2":0.059999999999999998,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Novo Holdings","highestDevelopmentStatusID":"1","companyTruncated":"Novo Nordisk \/ Novo Holdings"},{"orgOrder":0,"company":"Dicerna Pharmaceuticals","sponsor":"Veristat","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Nedosiran","moa":"LDH","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Dicerna Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Dicerna Pharmaceuticals \/ Veristat Inc","highestDevelopmentStatusID":"10","companyTruncated":"Dicerna Pharmaceuticals \/ Veristat Inc"},{"orgOrder":0,"company":"Dicerna Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Nedosiran","moa":"LDH","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Dicerna Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Dicerna Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Dicerna Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Dicerna Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"DCR-A1203","moa":"ALDH2","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Dicerna Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Dicerna Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Dicerna Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"FT-7051","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Forma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Forma Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Forma Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Dicerna Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Nedosiran","moa":"LDH","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Dicerna Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Dicerna Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Dicerna Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Dicerna Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Nedosiran","moa":"LDH","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Dicerna Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Dicerna Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Dicerna Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordisk \/ Not Applicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"PathAI, inc","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Semaglutide","moa":"GLP-1 receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Novo Nordisk","highestDevelopmentStatusID":"8","companyTruncated":"Novo Nordisk \/ Novo Nordisk"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordisk \/ Not Applicable"},{"orgOrder":0,"company":"Dicerna Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Belcesiran","moa":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Dicerna Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"Dicerna Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Dicerna Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Dicerna Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Acquisition","leadProduct":"DCR-NOVO1","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Novo Nordisk","amount2":3.2999999999999998,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":3.2999999999999998,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Novo Nordisk \/ Novo Nordisk","highestDevelopmentStatusID":"4","companyTruncated":"Novo Nordisk \/ Novo Nordisk"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Olutasidenib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Forma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Forma Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Forma Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Etavopivat","moa":"PKR","graph1":"Hematology","graph2":"Phase II\/ Phase III","graph3":"Forma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Forma Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Forma Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"2Seventy Bio","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"MegaTAL mRNA","moa":"","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Novo Nordisk","amount2":0.040000000000000001,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Novo Nordisk","highestDevelopmentStatusID":"1","companyTruncated":"Novo Nordisk \/ Novo Nordisk"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Eracal Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"SWITZERLAND","productType":"Peptide","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Discovery Platform","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Novo Nordisk","highestDevelopmentStatusID":"3","companyTruncated":"Novo Nordisk \/ Novo Nordisk"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Massachusetts Institute of Technology","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"Biologic Medicine","moa":"","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Massachusetts Institute of Technology","highestDevelopmentStatusID":"1","companyTruncated":"Novo Nordisk \/ Massachusetts Institute of Technology"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordisk \/ Not Applicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"DENMARK","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Eptacog Alfa","moa":"Coagulation cascade","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Not Applicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Insulin Icodec","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Not Applicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Flagship Pioneering","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Novo Nordisk \/ Novo Nordisk","highestDevelopmentStatusID":"2","companyTruncated":"Novo Nordisk \/ Novo Nordisk"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"FT-7051","moa":"CBP\/p300","graph1":"Oncology","graph2":"Phase I","graph3":"Forma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Forma Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Forma Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Ginkgo Bioworks","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Endocrinology","graph2":"Discovery","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Novo Nordisk","highestDevelopmentStatusID":"2","companyTruncated":"Novo Nordisk \/ Novo Nordisk"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Insulin Icodec","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Not Applicable"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Etavopivat","moa":"PKR","graph1":"Hematology","graph2":"Phase II\/ Phase III","graph3":"Forma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Forma Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Forma Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Somapacitan","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordisk \/ Not Applicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Concizumab","moa":"Tissue factor pathway","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Not Applicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Mim8","moa":"Factor VIII","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Not Applicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Insulin Icodec","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Not Applicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Marinus Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Divestment","leadProduct":"Ganaxolone","moa":"GABA A receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Novo Nordisk","amount2":0.11,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","amount2New":0.11,"dosageForm":"Suspension","sponsorNew":"Novo Nordisk \/ Novo Nordisk","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordisk \/ Novo Nordisk"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Rigel Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Olutasidenib","moa":"IDH1","graph1":"Oncology","graph2":"Phase II","graph3":"Forma Therapeutics","amount2":0.23999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.23999999999999999,"dosageForm":"Capsule","sponsorNew":"Forma Therapeutics \/ Rigel Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Forma Therapeutics \/ Rigel Pharmaceuticals"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordisk \/ Not Applicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Marinus Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"Ganaxolone","moa":"GABA A receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0.11,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.11,"dosageForm":"Suspension","sponsorNew":"Novo Nordisk \/ Novo Nordisk","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Novo Nordisk"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Aeterna Zentaris","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Termination","leadProduct":"Macimorelin","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Novo Nordisk \/ Novo Nordisk","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordisk \/ Novo Nordisk"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Zealand Pharma","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide","year":"2022","type":"Licensing Agreement","leadProduct":"Dasiglucagon","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Novo Nordisk","amount2":0.040000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0.040000000000000001,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Novo Nordisk","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordisk \/ Novo Nordisk"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Insulin Icodec","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Not Applicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Insulin Icodec","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Not Applicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Ventus Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"VENT-01","moa":"NLRP3","graph1":"Nephrology","graph2":"IND Enabling","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Novo Nordisk","highestDevelopmentStatusID":"5","companyTruncated":"Novo Nordisk \/ Novo Nordisk"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Forma Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Etavopivat","moa":"PKR","graph1":"Hematology","graph2":"Phase II\/ Phase III","graph3":"Novo Nordisk","amount2":1.1000000000000001,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Hematology","amount2New":1.1000000000000001,"dosageForm":"Tablet","sponsorNew":"Novo Nordisk \/ Novo Nordisk","highestDevelopmentStatusID":"9","companyTruncated":"Novo Nordisk \/ Novo Nordisk"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Prothena","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"IRELAND","productType":"Large molecule","year":"2022","type":"Acquisition","leadProduct":"NNC6019","moa":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Novo Nordisk","amount2":1.2,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":1.2,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Novo Nordisk","highestDevelopmentStatusID":"8","companyTruncated":"Novo Nordisk \/ Novo Nordisk"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Ventus Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"VENT-03","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Novo Nordisk","highestDevelopmentStatusID":"4","companyTruncated":"Novo Nordisk \/ Novo Nordisk"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordisk \/ Not Applicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Etavopivat","moa":"PKR","graph1":"Hematology","graph2":"Phase II\/ Phase III","graph3":"Novo Nordisk","amount2":1.1000000000000001,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Hematology","amount2New":1.1000000000000001,"dosageForm":"Tablet","sponsorNew":"Novo Nordisk \/ Novo Nordisk","highestDevelopmentStatusID":"9","companyTruncated":"Novo Nordisk \/ Novo Nordisk"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Ventus Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"VENT-01","moa":"NLRP3","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"IND Enabling","graph3":"Novo Nordisk","amount2":0.69999999999999996,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Hepatology","amount2New":0.69999999999999996,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Novo Nordisk","highestDevelopmentStatusID":"5","companyTruncated":"Novo Nordisk \/ Novo Nordisk"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Debiopharm","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"FT-3171","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Debiopharm","highestDevelopmentStatusID":"4","companyTruncated":"Novo Nordisk \/ Debiopharm"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Diabeloop","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide","year":"2023","type":"Collaboration","leadProduct":"Insulin","moa":"","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Novo Nordisk \/ Novo Nordisk","highestDevelopmentStatusID":"1","companyTruncated":"Novo Nordisk \/ Novo Nordisk"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Dewpoint Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Endocrinology","graph2":"Discovery Platform","graph3":"Novo Nordisk","amount2":0.75,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Endocrinology","amount2New":0.75,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Novo Nordisk","highestDevelopmentStatusID":"3","companyTruncated":"Novo Nordisk \/ Novo Nordisk"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordisk \/ Not Applicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Aspect Biosystems","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Cell and Gene therapy","year":"2023","type":"Collaboration","leadProduct":"Bioprinted-based Tissue Therapy","moa":"","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Novo Nordisk","amount2":2.6800000000000002,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":2.6800000000000002,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Novo Nordisk","highestDevelopmentStatusID":"1","companyTruncated":"Novo Nordisk \/ Novo Nordisk"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Concizumab","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordisk \/ Not Applicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordisk \/ Not Applicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"2Seventy Bio","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Novo Nordisk","amount2":0.040000000000000001,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Novo Nordisk","highestDevelopmentStatusID":"1","companyTruncated":"Novo Nordisk \/ Novo Nordisk"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Pathos","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"P-300","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novo Nordisk \/ Pathos","highestDevelopmentStatusID":"6","companyTruncated":"Novo Nordisk \/ Pathos"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Life Edit Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Discovery","graph3":"Novo Nordisk","amount2":1.9199999999999999,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Rare Diseases","amount2New":1.9199999999999999,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Novo Nordisk","highestDevelopmentStatusID":"2","companyTruncated":"Novo Nordisk \/ Novo Nordisk"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Somapacitan","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordisk \/ Not Applicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Zealand Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"Dasiglucagon","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Novo Nordisk \/ Novo Nordisk","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordisk \/ Novo Nordisk"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordisk \/ Not Applicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inversago Pharma","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"CANADA","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"INV-202","moa":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Novo Nordisk","amount2":1.0800000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":1.0800000000000001,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Novo Nordisk","highestDevelopmentStatusID":"8","companyTruncated":"Novo Nordisk \/ Novo Nordisk"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"DENMARK","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Not Applicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordisk \/ Not Applicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Undisclosed","year":"2023","type":"Acquisition","leadProduct":"Undisclosed","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Discovery","graph3":"Novo Nordisk","amount2":0.51000000000000001,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.51000000000000001,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Novo Nordisk","highestDevelopmentStatusID":"2","companyTruncated":"Novo Nordisk \/ Novo Nordisk"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Valo Health","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery Platform","graph3":"Novo Nordisk","amount2":2.7599999999999998,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":2.7599999999999998,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Novo Nordisk","highestDevelopmentStatusID":"3","companyTruncated":"Novo Nordisk \/ Novo Nordisk"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Evotec","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"DENMARK","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery Platform","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Evotec","highestDevelopmentStatusID":"3","companyTruncated":"Novo Nordisk \/ Evotec"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordisk \/ Not Applicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"KBP Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Ocedurenone","moa":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":1.3,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":1.3,"dosageForm":"Tablet","sponsorNew":"Novo Nordisk \/ Novo Nordisk","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Novo Nordisk"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"DENMARK","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Nedosiran","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Pre-Filled Syringe","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordisk \/ Not Applicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Genevant Sciences","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Novo Nordisk","highestDevelopmentStatusID":"2","companyTruncated":"Novo Nordisk \/ Novo Nordisk"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Insulin Icodec","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Not Applicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Omega Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Discovery Platform","graph3":"Novo Nordisk","amount2":0.53000000000000003,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.53000000000000003,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Novo Nordisk","highestDevelopmentStatusID":"3","companyTruncated":"Novo Nordisk \/ Novo Nordisk"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Cellarity","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Discovery Platform","graph3":"Novo Nordisk","amount2":0.53000000000000003,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Hepatology","amount2New":0.53000000000000003,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Novo Nordisk","highestDevelopmentStatusID":"3","companyTruncated":"Novo Nordisk \/ Novo Nordisk"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Eracal Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"SWITZERLAND","productType":"Small molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Discovery Platform","graph3":"Novo Nordisk","amount2":0.26000000000000001,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.26000000000000001,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Novo Nordisk","highestDevelopmentStatusID":"3","companyTruncated":"Novo Nordisk \/ Novo Nordisk"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Almirall","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Large molecule","year":"2024","type":"Licensing Agreement","leadProduct":"NN-8828","moa":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Almirall","highestDevelopmentStatusID":"4","companyTruncated":"Novo Nordisk \/ Almirall"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Neomorph","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery Platform","graph3":"Novo Nordisk","amount2":1.46,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":1.46,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Novo Nordisk","highestDevelopmentStatusID":"3","companyTruncated":"Novo Nordisk \/ Novo Nordisk"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Insulin Icodec","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Not Applicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Cardior Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Large molecule","year":"2024","type":"Acquisition","leadProduct":"CDR132L","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Novo Nordisk","amount2":1.1100000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":1.1100000000000001,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Novo Nordisk","highestDevelopmentStatusID":"8","companyTruncated":"Novo Nordisk \/ Novo Nordisk"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordisk \/ Not Applicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordisk \/ Not Applicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Amycretin","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Novo Nordisk \/ Not Applicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"DENMARK","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordisk \/ Not Applicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Ginkgo Bioworks","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Endocrinology","graph2":"Discovery","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Novo Nordisk","highestDevelopmentStatusID":"2","companyTruncated":"Novo Nordisk \/ Novo Nordisk"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"NNC6022-0001","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Novo Nordisk \/ Not Applicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Metaphore Biotechnologies","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Discovery Platform","graph3":"Novo Nordisk","amount2":0.59999999999999998,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.59999999999999998,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Novo Nordisk","highestDevelopmentStatusID":"3","companyTruncated":"Novo Nordisk \/ Novo Nordisk"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Mim8","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Not Applicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Insulin Icodec","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Not Applicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Biosplice","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Novo Nordisk","highestDevelopmentStatusID":"4","companyTruncated":"Novo Nordisk \/ Novo Nordisk"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"2Seventy Bio","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Divestment","leadProduct":"Undisclosed","moa":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Novo Nordisk","amount2":0.040000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Novo Nordisk","highestDevelopmentStatusID":"4","companyTruncated":"Novo Nordisk \/ Novo Nordisk"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"DENMARK","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Ocedurenone","moa":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Not Applicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordisk \/ Not Applicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Mim8","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordisk \/ Not Applicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordisk \/ Not Applicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Insulin Icodec","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordisk \/ Not Applicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"DENMARK","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordisk \/ Not Applicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordisk \/ Not Applicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Korro Bio","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Collaboration","leadProduct":"RNA-based Therapy","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Novo Nordisk","amount2":0.53000000000000003,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Novo Nordisk","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordisk \/ Novo Nordisk"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"NanoVation Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Large molecule","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Novo Nordisk","amount2":0.59999999999999998,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Novo Nordisk","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordisk \/ Novo Nordisk"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"NanoVation Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"CANADA","productType":"Large molecule","year":"2024","type":"Partnership","leadProduct":"RNA-based Therapy","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Novo Nordisk","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordisk \/ Novo Nordisk"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"DENMARK","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordisk \/ Not Applicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Kallyope","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Licensing Agreement","leadProduct":"Peptide-based Therapy","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Novo Nordisk","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordisk \/ Novo Nordisk"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Liraglutide","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordisk \/ Not Applicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Monlunabant","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordisk \/ Not Applicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Amycretin","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordisk \/ Not Applicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Liraglutide","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordisk \/ Not Applicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Concizumab","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordisk \/ Not Applicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Ascendis Pharma","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Novo Nordisk","amount2":0.28999999999999998,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Novo Nordisk","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordisk \/ Novo Nordisk"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"DENMARK","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordisk \/ Not Applicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"DENMARK","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordisk \/ Not Applicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordisk \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Novo Nordisk

    Menu

    Novo Nordisk

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Novo Nordisk

                            Denmark arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Novo Nordisk

                            Denmark arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Semaglutide

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Novo Nordisk Launches Obesity Drug Wegovy in China

                            Details : Wegovy (semaglutide) is a GLP-1 receptor agonist indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management & treatment of obesity.

                            Brand Name : Wegovy

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            November 18, 2024

                            Lead Product(s) : Semaglutide

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Novo Nordisk

                            Denmark arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Novo Nordisk

                            Denmark arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Preclinical

                            Recipient : Ascendis Pharma

                            Deal Size : $285.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Ascendis And Novo Nordisk Collaborate on TransCon Tech Products

                            Details : Novo gains an exclusive worldwide license to TransCon technology platform to develop, manufacture and commercialize its proprietary products in metabolic diseases (obesity and type 2 diabetes).

                            Brand Name : Undisclosed

                            Molecule Type : Undisclosed

                            Upfront Cash : Undisclosed

                            November 04, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Preclinical

                            Recipient : Ascendis Pharma

                            Deal Size : $285.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Novo Nordisk

                            Denmark arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Novo Nordisk

                            Denmark arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Semaglutide

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            SELECT Trial Shows Semaglutide Reduces Hospital Admissions in Heart Disease Patients

                            Details : Wegovy (semaglutide) is a GLP-1 receptor agonist being investigated for the treatment of adults with obesity or overweight with established cardiovascular disease (CVD) and without diabetes.

                            Brand Name : Wegovy

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            November 03, 2024

                            Lead Product(s) : Semaglutide

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Novo Nordisk

                            Denmark arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Novo Nordisk

                            Denmark arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Semaglutide

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Novo Nordisk’s Semaglutide Excels in Liver Fibrosis and MASH Resolution in ESSENCE Trial

                            Details : Wegovy (semaglutide) is a GLP-1 receptor agonist being investigated for the treatment of adults with metabolic dysfunction-associated steatohepatitis (MASH) and moderate to advanced liver fibrosis.

                            Brand Name : Wegovy

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            November 01, 2024

                            Lead Product(s) : Semaglutide

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Novo Nordisk

                            Denmark arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Novo Nordisk

                            Denmark arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Concizumab

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Alhemo® Recommended in EU As Daily Treatment for Hemophilia with Inhibitors

                            Details : Alhemo™ (concizumab) is the first anti-TFPI (Tissue Factor Pathway Inhibitor) approved by health canada for the treatment for people living with Hemophilia B in patients over the age of 12.

                            Brand Name : Alhemo

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            October 18, 2024

                            Lead Product(s) : Concizumab

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Novo Nordisk

                            Denmark arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Novo Nordisk

                            Denmark arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Monlunabant

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Novo Nordisk A/S: Monlunabant Phase 2a Trial in Obesity Completed

                            Details : INV-202 (monlunabant) is an inverse agonist of the CB1 receptor being investigated for obesity and metabolic syndrome.

                            Brand Name : INV-202

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 20, 2024

                            Lead Product(s) : Monlunabant

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Novo Nordisk

                            Denmark arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Novo Nordisk

                            Denmark arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Discovery Platform

                            Recipient : NanoVation Therapeutics

                            Deal Size : $600.0 million

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            NanoVation Partners with Novo Nordisk For Cardiometabolic And Rare Genetic Medicines

                            Details : Novo and NanoVation will be partnering for two lead programs to develop base-editing therapies for certain rare genetic diseases, and up to five additional future targets for cardiometabolic diseases.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            September 18, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Discovery Platform

                            Recipient : NanoVation Therapeutics

                            Deal Size : $600.0 million

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Novo Nordisk

                            Denmark arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Novo Nordisk

                            Denmark arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RNA-based Therapy

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Discovery Platform

                            Recipient : NanoVation Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Novo Nordisk Bets $600M on NanoVation for Genetic Medicines Beyond Liver

                            Details : The partnership combines NanoVation’s proprietary lcLNP™ technology for RNA delivery with Novo Nordisk’s expertise in cardiometabolic and rare disease R&D and clinical translation.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : $600.0 million

                            September 18, 2024

                            Lead Product(s) : RNA-based Therapy

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Discovery Platform

                            Recipient : NanoVation Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Novo Nordisk

                            Denmark arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Novo Nordisk

                            Denmark arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RNA-based Therapy

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Discovery Platform

                            Recipient : Korro Bio

                            Deal Size : $530.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Korro Bio Announces Collaboration with Novo Nordisk to Develop Two Therapeutic Candidates

                            Details : The collaboration brings together Novo's deep cardiometabolic disease understanding and drug development experience with Korro’s platform to develop RNA editing product candidates.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            September 16, 2024

                            Lead Product(s) : RNA-based Therapy

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Discovery Platform

                            Recipient : Korro Bio

                            Deal Size : $530.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Novo Nordisk

                            Denmark arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Novo Nordisk

                            Denmark arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Peptide-based Therapy

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Discovery

                            Recipient : Kallyope

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Kallyope Announces License Agreement with Novo Nordisk

                            Details : Under the terms of the license agreement, Novo Nordisk will discover novel peptide therapeutics including as a potential new mechanism for the treatment of obesity.

                            Brand Name : Undisclosed

                            Molecule Type : Peptide

                            Upfront Cash : Undisclosed

                            September 10, 2024

                            Lead Product(s) : Peptide-based Therapy

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Discovery

                            Recipient : Kallyope

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth